Laverock Therapeutics Extends Seed Round to £20m
Deal News | Jul 01, 2025 | UK Tech Funding
Laverock Therapeutics, a life sciences startup focused on gene control technology, announced the extension of its seed funding round to over £20 million. The company initially raised £13.5 million in 2023 and has now secured additional investment to further its platform development and support therapeutic collaborations. New investor Calculus Capital led the extension, joined by existing supporters such as Eli Lilly and Company, Mercia Ventures, Eos Advisory, and Maven Capital Partners. The capital will enable Laverock Therapeutics to strengthen its technology platform and derive functional data for its therapeutic programs. CEO David Venables emphasized the support from investors as instrumental in driving product development and delivering investor value.
Sectors
- Life Sciences
- Biotechnology
- Financial Services
Geography
- United Kingdom – Laverock Therapeutics is based in the UK and the funding round is led by UK-based investors.
Industry
- Life Sciences – Laverock Therapeutics operates within the life sciences sector, focusing on gene control technology for advanced therapies.
- Biotechnology – The article involves biotechnology as it discusses advancements in genetic control technologies aimed at developing advanced therapies.
- Financial Services – The participation of investment firms such as Calculus Capital underscores the involvement of financial services in providing funding.
Financials
- £20 million – Total amount raised in the seed round extension by Laverock Therapeutics.
- £13.5 million – Initial amount raised during Laverock Therapeutics' 2023 seed round.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Laverock Therapeutics | Target Company | Company | A life sciences startup specializing in gene control technologies for developing advanced therapies. |
| Calculus Capital | Lead Investor | Company | An investment firm leading the seed extension funding for Laverock Therapeutics. |
| Eli Lilly and Company | Existing Investor | Company | A global pharmaceutical company participating as an existing investor in Laverock Therapeutics. |
| Mercia Ventures | Existing Investor | Company | A venture capital firm supporting Laverock Therapeutics as an existing investor. |
| Eos Advisory | Existing Investor | Company | An investment firm involved as an existing investor in Laverock Therapeutics. |
| Maven Capital Partners | Existing Investor | Company | A private equity firm participating as an existing investor in the funding round. |
| Norcliffe Capital | Investor | Company | Participated as an investor in the seed extension round for Laverock Therapeutics. |
| David Venables | CEO | People | Chief Executive Officer of Laverock Therapeutics, leading the company's advancements in gene control technology. |
| Elizabeth Klein | Investment Director | People | Investment Director at Calculus Capital, involved in the seed extension round for Laverock Therapeutics. |